CagriSema
Also referenced as: Cagrilintide + semaglutide
An investigational combination of cagrilintide and semaglutide, distinct from either component alone.
- Evidence grade
- BModerate Human Evidence
Moderate Human Evidence
- Regulatory status
- Clinical Trials
Investigational in the sponsor’s October 2026 update. A US application was submitted in December 2025; submission is not approval.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
An investigational combination of cagrilintide and semaglutide, distinct from either component alone.
Investigational in the sponsor’s October 2026 update. A US application was submitted in December 2025; submission is not approval.
Efficacy-estimand results assume adherence; approval of semaglutide does not approve the combination.
Why It's Being Studied
- Obesity research
- Type 2 diabetes research
- Combination therapy
Mechanism of Action
Amylin-receptor and GLP-1-receptor agonism combine complementary effects on satiety and metabolic regulation.
Amylin-receptor and GLP-1-receptor agonism combine complementary effects on satiety and metabolic regulation. Efficacy-estimand results assume adherence; approval of semaglutide does not approve the combination.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Obesity research
- Type 2 diabetes research
- Combination therapy
- Subcutaneous clinical research
Evidence Summary
Phase 3 studies support weight and glycemic effects. A 2026 head-to-head trial did not meet its noninferiority primary endpoint against tirzepatide.
Higher tiers carry more weight. Filled tiers have evidence for CagriSema; tap to read it.
- Phase 3 studies support weight and glycemic effects. A 2026 head-to-head trial did not meet its noninferiority primary endpoint against tirzepatide.
1 cited sources.
- Regulatory document1
Human clinical evidence
- Phase 3 studies support weight and glycemic effects. A 2026 head-to-head trial did not meet its noninferiority primary endpoint against tirzepatide.
Reported Adverse Events in Research
- Gastrointestinal intolerance and treatment discontinuation matter when interpreting weight-loss estimates.
Limitations of Current Evidence
- Efficacy-estimand results assume adherence; approval of semaglutide does not approve the combination.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| CagriSema | Trofinetide | |
|---|---|---|
| Evidence grade | B — Moderate Human Evidence | B — Moderate Human Evidence |
| Regulatory status | Clinical Trials | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous clinical research | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Regulatory document
CagriSema — regulatory document